[HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy]

Duodecim. 2000;116(15):1538-46.
[Article in Finnish]
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / genetics
  • Breast Neoplasms / therapy*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Prognosis
  • Receptor, ErbB-2 / genetics*
  • Receptor, ErbB-2 / immunology*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab